Rising Drug Costs: Are Pharmaceutical Benefit Managers to Blame?
For many Americans, the rising tide of prescription drug prices seems like an unstoppable force, threatening to drown household budgets and access to health care. While pharmaceutical companies often shoulder the brunt of the public blame, the web of influence on drug costs is far more intricate. Today, we shine a spotlight on a critical but usually hidden player in this system: pharmacy benefit managers, or PBMs. Rebecca Robbins, a leading investigative reporter specializing in pharmaceuticals for The New York Times, takes us on a deep dive into the world of PBMs. We explore their role as middlemen between drugmakers,…
